CGBio said on Friday that it would launch Novomax Fusion, a ceramic-based cervical fusion cage that it had independently developed, to the Japanese spinal implant market. It is the first CGBio spinal implant product to be introduced to the Japanese market.

Novomax Fusion is a third-generation cervical spine cage that utilizes BGS-7 (calcium-silica-phosphorus-boron composition), a new bioactive glass-ceramic material developed by CGBio. The product is more biocompatible than existing titanium or PEEK cages, and it also exhibits excellent osteoconductivity, creating an environment that facilitates bone growth. When inserted into the body, fusion is achieved by directly attaching the bone to the surface of the cage, and stable bone fusion can be induced without the need for a separate bone graft material.

Based on this technology, CGBio signed a supply agreement with Nippon Zoki Pharmaceutical, a leading mid-sized pharmaceutical company in Japan, this year.

Founded in Osaka, Japan, in 1939, Nippon Zoki Pharmaceutical is a company specializing in the treatment of chronic pain in the fields of orthopedics and neurosurgery. Last year, it established ZSpine, a distribution company specializing in spinal implants, as a subsidiary.

Novomax Fusion will be supplied to the Japanese market through ZSpine. This agreement marks CGBio's first entry into the Japanese market with an official distribution partner.

“By the entry of Novomax Fusion, we have once again demonstrated the superiority and clinical potential of our new BGS-7 material in Japan, which is recognized as a technology leader,” CGBio CEO Yu Hyun-seung said. “We plan to enter the global market for our next-generation spinal implant family, including the expandable cage Excender.”